Supernus Pharmaceuticals, Inc. (SUPN) Expected to Post Quarterly Sales of $76.19 Million

Wall Street brokerages expect that Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) will report $76.19 million in sales for the current quarter, Zacks Investment Research reports. Four analysts have made estimates for Supernus Pharmaceuticals’ earnings, with estimates ranging from $72.88 million to $79.04 million. Supernus Pharmaceuticals reported sales of $56.81 million during the same quarter last year, which would suggest a positive year-over-year growth rate of 34.1%. The firm is expected to announce its next quarterly earnings report on Friday, January 19th.

According to Zacks, analysts expect that Supernus Pharmaceuticals will report full year sales of $76.19 million for the current fiscal year, with estimates ranging from $290.99 million to $297.51 million. For the next fiscal year, analysts expect that the business will post sales of $379.78 million per share, with estimates ranging from $371.36 million to $384.69 million. Zacks Investment Research’s sales averages are a mean average based on a survey of research analysts that cover Supernus Pharmaceuticals.

Supernus Pharmaceuticals (NASDAQ:SUPN) last posted its quarterly earnings results on Wednesday, August 2nd. The specialty pharmaceutical company reported $0.32 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.24 by $0.08. The company had revenue of $75.83 million for the quarter, compared to the consensus estimate of $68.54 million. Supernus Pharmaceuticals had a net margin of 41.10% and a return on equity of 30.73%.

Several research firms recently commented on SUPN. Zacks Investment Research upgraded shares of Supernus Pharmaceuticals from a “hold” rating to a “buy” rating and set a $49.00 price target for the company in a report on Thursday, July 13th. Piper Jaffray Companies cut shares of Supernus Pharmaceuticals from an “overweight” rating to a “neutral” rating and set a $46.00 price target for the company. in a report on Monday, July 17th. BidaskClub upgraded shares of Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Saturday, June 24th. Janney Montgomery Scott began coverage on shares of Supernus Pharmaceuticals in a report on Friday, July 14th. They set a “neutral” rating and a $47.00 price target for the company. Finally, Cantor Fitzgerald raised their price target on shares of Supernus Pharmaceuticals from $34.00 to $49.00 and gave the stock a “buy” rating in a report on Wednesday, July 5th. Four equities research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of $48.43.

In other Supernus Pharmaceuticals news, VP Padmanabh P. Bhatt sold 3,735 shares of Supernus Pharmaceuticals stock in a transaction that occurred on Wednesday, July 12th. The shares were sold at an average price of $44.90, for a total value of $167,701.50. Following the completion of the sale, the vice president now directly owns 21,209 shares in the company, valued at $952,284.10. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Padmanabh P. Bhatt sold 2,556 shares of the business’s stock in a transaction on Friday, June 23rd. The stock was sold at an average price of $44.90, for a total transaction of $114,764.40. Following the completion of the sale, the vice president now owns 24,944 shares of the company’s stock, valued at $1,119,985.60. The disclosure for this sale can be found here. Insiders sold 24,291 shares of company stock valued at $962,766 over the last quarter. Corporate insiders own 6.70% of the company’s stock.

Several hedge funds have recently modified their holdings of SUPN. Meeder Asset Management Inc. boosted its stake in shares of Supernus Pharmaceuticals by 3,455.2% in the second quarter. Meeder Asset Management Inc. now owns 2,382 shares of the specialty pharmaceutical company’s stock worth $103,000 after buying an additional 2,315 shares during the last quarter. Ameritas Investment Partners Inc. purchased a new stake in shares of Supernus Pharmaceuticals during the first quarter worth $127,000. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in shares of Supernus Pharmaceuticals by 278.2% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,018 shares of the specialty pharmaceutical company’s stock worth $130,000 after buying an additional 2,220 shares during the last quarter. Victory Capital Management Inc. boosted its stake in shares of Supernus Pharmaceuticals by 17.7% in the second quarter. Victory Capital Management Inc. now owns 3,441 shares of the specialty pharmaceutical company’s stock worth $148,000 after buying an additional 517 shares during the last quarter. Finally, Fortaleza Asset Management Inc. purchased a new stake in shares of Supernus Pharmaceuticals during the first quarter worth $160,000. Institutional investors and hedge funds own 94.39% of the company’s stock.

Supernus Pharmaceuticals (NASDAQ SUPN) opened at 41.70 on Wednesday. The stock has a market cap of $2.11 billion, a P/E ratio of 21.05 and a beta of 1.31. The firm’s 50-day moving average is $42.46 and its 200-day moving average is $33.49. Supernus Pharmaceuticals has a 1-year low of $17.25 and a 1-year high of $44.95.

TRADEMARK VIOLATION WARNING: This piece was originally posted by BNB Daily and is owned by of BNB Daily. If you are accessing this piece on another domain, it was copied illegally and reposted in violation of United States & international copyright laws. The correct version of this piece can be read at https://www.baseball-news-blog.com/2017/08/19/supernus-pharmaceuticals-inc-supn-expected-to-post-quarterly-sales-of-76-19-million-updated.html.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy.

Get a free copy of the Zacks research report on Supernus Pharmaceuticals (SUPN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Supernus Pharmaceuticals (NASDAQ:SUPN)

Receive News & Ratings for Supernus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply